|
2020 Journal Article Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidanceWeinkove, Robert, McQuilten, Zoe K, Adler, Jonathan, Agar, Meera R, Blyth, Emily, Cheng, Allen C, Conyers, Rachel, Haeusler, Gabrielle M, Hardie, Claire, Jackson, Christopher, Lane, Steven W, Middlemiss, Tom, Mollee, Peter, Mulligan, Stephen P, Ritchie, David, Ruka, Myra, Solomon, Benjamin, Szer, Jeffrey, Thursky, Karin A, Wood, Erica M, Worth, Leon J, Yong, Michelle K, Slavin, Monica A and Teh, Benjamin W (2020). Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance. Medical Journal of Australia, 212 (10) mja2.50607, 481-489. doi: 10.5694/mja2.50607 |
|
2020 Journal Article Bortezomib use and outcomes for the treatment of multiple myelomaLoke, Crystal, Mollee, Peter, McPherson, Ian, Walpole, Euan, Yue, Mimi, Mutsando, Howard, Wong, Phillip, Weston, Helen, Tomlinson, Ross and Hollingworth, Samantha (2020). Bortezomib use and outcomes for the treatment of multiple myeloma. Internal Medicine Journal, 50 (9) imj.14886, 1059-1066. doi: 10.1111/imj.14886 |
|
2020 Journal Article A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working GroupMaqbool, M. Gohar, Tam, Constantine S., Morison, Ian M., Simpson, David, Mollee, Peter, Schneider, Hans, Chan, Henry, Juneja, Surender, Harvey, Yasmin, Nath, Lakshmi, Hissaria, Pravin, Prince, H. Miles, Wordsworth, Helen, Opat, Stephen and Talaulikar, Dipti (2020). A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group. Pathology, 52 (2), 167-178. doi: 10.1016/j.pathol.2019.11.002 |
|
2020 Journal Article Concurrent lipidomics and proteomics on malignant plasma cells from multiple myeloma patients: Probing the lipid metabolomeMohamed, Ahmed, Collins, Joel, Jiang, Hui, Molendijk, Jeffrey, Stoll, Thomas, Torta, Federico, Wenk, Markus R., Bird, Robert J., Marlton, Paula, Mollee, Peter, Markey, Kate A. and Hill, Michelle M. (2020). Concurrent lipidomics and proteomics on malignant plasma cells from multiple myeloma patients: Probing the lipid metabolome. PloS One, 15 (1) e0227455, e0227455. doi: 10.1371/journal.pone.0227455 |
|
2020 Conference Publication 99Tc-DPD Bone scintigraphy correlates with left ventricular wall thickness and global longitudinal strain in patients with ATTR wild type cardiac amyloidosisRobinson, J., Burrage, M., Ngai, S., Mackenzie, E., Duong, J., Mollee, P. and Korczyk, D. (2020). 99Tc-DPD Bone scintigraphy correlates with left ventricular wall thickness and global longitudinal strain in patients with ATTR wild type cardiac amyloidosis. 68th Cardiac Society of Australia and New Zealand Annual Scientific Meeting, the International Society for Heart Research Australasian Section Annual Scientific Meeting and the 14th Annual Australia and New Zealand Endovascular Therapies Meeting, Online, 11-13 December 2020. Chatswood, NSW Australia: Elsevier. doi: 10.1016/j.hlc.2020.09.069 |
|
2020 Conference Publication Changing picture of ATTR wild type cardiomyopathy in Australia – Queensland Amyloidosis Centre experienceKorczyk, D., Woodcroft-Brown, V., Maffey, M. and Mollee, P. (2020). Changing picture of ATTR wild type cardiomyopathy in Australia – Queensland Amyloidosis Centre experience. 68th Cardiac Society of Australia and New Zealand Annual Scientific Meeting, the International Society for Heart Research Australasian Section Annual Scientific Meeting and the 14th Annual Australia and New Zealand Endovascular Therapies Meeting, Online, 11-13 December 2020. Chatswood, NSW Australia: Elsevier. doi: 10.1016/j.hlc.2020.09.100 |
|
2019 Conference Publication Real-World Outcome for Newly Diagnosed Patients with Functional High-Risk Myeloma - a Myeloma and Related Diseases Registry AnalysisSpencer, Andrew, Mollee, Peter, Blacklock, Hilary Anne, Harrison, Simon, Quach, Hang, Ho, P. Joy, Spearing, Ruth, Hocking, Jay, Augustson, Bradley, Prince, H. Miles, Moore, Elizabeth M., McQuilten, Zoe, Wood, Erica M. and Wellard, Cameron (2019). Real-World Outcome for Newly Diagnosed Patients with Functional High-Risk Myeloma - a Myeloma and Related Diseases Registry Analysis. 61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Orlando Fl, Dec 05-10, 2019. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2019-129431 |
|
2019 Conference Publication Identification of Novel Immune Cell Populations in Lenalidomide Refractory Relapsed Multiple Myeloma Patients Treated with Pomalidomide and Low Dose DexamethasoneKalff, Anna, Khong, Tiffany, Ramachandran, Malarmathy, Norton, Sam, Mitchell, Andrew, Reynolds, John, Quach, Hang, Ho, P. Joy, Horvath, Noemi, Mollee, Peter, Kennedy, Nola, Kemp, Roslyn and Spencer, Andrew (2019). Identification of Novel Immune Cell Populations in Lenalidomide Refractory Relapsed Multiple Myeloma Patients Treated with Pomalidomide and Low Dose Dexamethasone. 61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Orlando Fl, Dec 05-10, 2019. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2019-130154 |
|
2019 Journal Article Trends in myeloma relative survival in Queensland by treatment era, age, place of residence, and socioeconomic statusHarwood, Matthew, Dunn, Nathan, Moore, Julie, Mollee, Peter and Hapgood, Greg (2019). Trends in myeloma relative survival in Queensland by treatment era, age, place of residence, and socioeconomic status. Leukemia & Lymphoma, 61 (3), 1-7. doi: 10.1080/10428194.2019.1688322 |
|
2019 Journal Article Combination bone marrow imaging using positron emission tomography (PET)-MRI in plasma cell dyscrasias: correlation with prognostic laboratory values and clinicopathological diagnosisTate, Courtney J., Mollee, Peter N. and Miles, Kenneth A. (2019). Combination bone marrow imaging using positron emission tomography (PET)-MRI in plasma cell dyscrasias: correlation with prognostic laboratory values and clinicopathological diagnosis. BJR|Open, 1 (1) 20180020, 20180020. doi: 10.1259/bjro.20180020 |
|
2019 Conference Publication Significantly improved relative survival of patients with myeloma in Queensland with treatment advancesMollee, Peter, Harwood, Matthew, Dunn, Nathan, Moore, Julie and Hapgood, Greg (2019). Significantly improved relative survival of patients with myeloma in Queensland with treatment advances. 17th International Myeloma Workshop, Boston, MA, 12-15 September 2019. Dallas: CIG Media Group. doi: 10.1016/j.clml.2019.09.387 |
|
2019 Conference Publication Development of an individualized, supervised exercise intervention as standard care for patients with multiple MyelomaNicol, Jennifer, Woodrow, Carmel, Burton, Nicola, Hill, Michelle, Skinner, Tina, Mollee, Peter and Nicol, Andrew (2019). Development of an individualized, supervised exercise intervention as standard care for patients with multiple Myeloma. 17th International Myeloma Workshop, Boston, MA United States, 12-15 September 2019. New York, NY United States: Elsevier . doi: 10.1016/j.clml.2019.09.355 |
|
2019 Conference Publication Receiving four or less cycles of therapy predicts poor survival in newly diagnosed transplant ineligible patients with myeloma who are treated with bortezomib-based inductionMollee, Peter, Boyle, Stephen, Wellard, Cameron, Moore, Elizabeth, Blacklock, Hilary, Harrison, Simon J., Ho, P. Joy, Hocking, Jay, McQuilten, Zoe, Quach, Hang, Spearing, Ruth, Wood, Erica and Spencer, Andrew (2019). Receiving four or less cycles of therapy predicts poor survival in newly diagnosed transplant ineligible patients with myeloma who are treated with bortezomib-based induction. 17th International Myeloma Workshop, Boston, MA United States, 12 - 15 September 2019. New York, NY United States: Elsevier. doi: 10.1016/j.clml.2019.09.388 |
|
2019 Conference Publication Pacific Islanders with multiple myeloma are younger and have inferior survival when compared to other ethnicities: a study from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)Blacklock, Hilary, Moore, Elizabeth, Wellard, Cameron, Harrison, Simon J., Ho, P. Joy, Hocking, Jay, McQuilten, Zoe, Mollee, Peter, Quach, Hang, Spearing, Ruth, Wood, Erica and Spencer, Andrew (2019). Pacific Islanders with multiple myeloma are younger and have inferior survival when compared to other ethnicities: a study from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). 17th International Myeloma Workshop, Boston, MA, 12-15 September 2019. Dallas: CIG Media Group. doi: 10.1016/j.clml.2019.09.354 |
|
2019 Conference Publication Daratumumab, lenalidomide, and dexamethasone (d-rd) delivers a reduction and delay in worsening of pain symptoms for patients with newly diagnosed multiple myeloma ineligible for transplantGries, Katharine, Facon, Thierry, Plesner, Torben, Usmani, Saad, Kumar, Shaji, Orlowski, Robert Z., Bahlis, Nizar J., Nahi, Hareth, Mollee, Peter, Ramasamy, Karthik, Roussel, Murielle, Delforge, Michel, Karlin, Lionel, Arnulf, Bertrand, Chari, Ajai, Hulin, Cyrille, Weisel, Katja, He, Jianming, Ho, Kai Fai, Wang, Jim, Van Rampelbergh, Rian, Uhlar, Clarissa, Kobos, Rachel and Perrot, Aurore (2019). Daratumumab, lenalidomide, and dexamethasone (d-rd) delivers a reduction and delay in worsening of pain symptoms for patients with newly diagnosed multiple myeloma ineligible for transplant. 17th International Myeloma Workshop, Boston, MA, 12-15 September 2019. Dallas: CIG Media Group. doi: 10.1016/j.clml.2019.09.375 |
|
2019 Journal Article Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma AllianceTobin, Joshua W. D., Rule, Gabrielle, Colvin, Katherine, Calvente, Lourdes, Hodgson, David, Bell, Stephen, Dunduru, Chengetai, Gallo, James, Tsang, Erica S., Tan, Xuan, Wong, Jonathan, Pearce, Jessica, Campbell, Robert, Tneh, Shao, Shorten, Sophie, Ng, Melissa, Cochrane, Tara, Tam, Constantine S., Abro, Emad, Hawkes, Eliza, Hodges, Georgina, Kansara, Roopesh, Talaulikar, Dipti, Gilbertson, Michael, Johnston, Anna M., Savage, Kerry J., Villa, Diego, Morris, Kirk, Ratnasingam, Sumi ... Hapgood, Greg (2019). Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance. Blood Advances, 3 (19), 2804-2811. doi: 10.1182/bloodadvances.2019000458 |
|
2019 Journal Article Progression of disease within 24 months in follicular lymphoma is associated with reduced intratumoral immune infiltrationTobin, Joshua W. D., Keane, Colm, Gunawardana, Jay, Mollee, Peter, Birch, Simone, Hoang, Thanh, Lee, Justina, Li, Li, Huang, Li, Murigneux, Valentine, Fink, J. Lynn, Matigian, Nicholas, Vari, Frank, Francis, Santiyagu, Kridel, Robert, Weigert, Oliver, Haebe, Sarah, Jurinovic, Vindi, Klapper, Wolfram, Steidl, Christian, Sehn, Laurie H., Law, Soi-Cheng, Wykes, Michelle N. and Gandhi, Maher K. (2019). Progression of disease within 24 months in follicular lymphoma is associated with reduced intratumoral immune infiltration. Journal of Clinical Oncology, 37 (34), 3300-3309. doi: 10.1200/JCO.18.02365 |
|
2019 Journal Article Renal impairment at diagnosis in myeloma: Patient characteristics, treatment, and impact on outcomes. Results trom the Australia and New Zealand myeloma and related diseases registryHo, P. Joy, Moore, Elizabeth M., McQuilten, Zoe K., Wellard, Cameron, Bergin, Krystal, Augustson, Bradley, Blacklock, Hilary, Harrison, Simon J., Horvath, Noemi, King, Tracy, Mollee, Peter, Quach, Hang, Reid, Christopher, Rosengarten, Brian, Walker, Patricia, Wood, Erica M. and Spencer, Andrew (2019). Renal impairment at diagnosis in myeloma: Patient characteristics, treatment, and impact on outcomes. Results trom the Australia and New Zealand myeloma and related diseases registry. Clinical Lymphoma, Myeloma and Leukemia, 19 (8), e415-e424. doi: 10.1016/j.clml.2019.05.010 |
|
2019 Conference Publication Lysozyme amyloidosis – Two novel cases with newly described genetic mutationsMcMichael, L., Chang, S., Gibbs, S., Mollee, P., Gillmore, J., Horvath, N., Crail, S. and Jobert, A. (2019). Lysozyme amyloidosis – Two novel cases with newly described genetic mutations. ISN World Congress of Nephrology (WCN) 2024, Buenos Aires, Argentina, 13-16 April 2024. New York, NY United States: Elsevier. doi: 10.1016/j.ekir.2019.05.590 |
|
2019 Journal Article High serum levels of CD178 (soluble FasL) predict for inferior progression free survival in chronic lymphocytic leukemia treated with fludarabine-based chemotherapyTate, Courtney, Burgess, Melinda, McMillan, Nigel A., Saunders, Nicholas A., Cheung, Catherine, Gill, Devinder and Mollee, Peter (2019). High serum levels of CD178 (soluble FasL) predict for inferior progression free survival in chronic lymphocytic leukemia treated with fludarabine-based chemotherapy. Leukemia and Lymphoma, 60 (10), 1-5. doi: 10.1080/10428194.2019.1581936 |
